Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWP1BH)

Drug Name
Tazemetostat Drug Info
Synonyms
EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-
Indication
Disease Entry ICD 11 Status REF
Follicular lymphoma 2A80 Approved [1]
Brain and central nervous system tumour 2A00.11 Phase 2 [2]
Malignant rhabdoid tumour 2A00.1Y Phase 2 [3]
Mesothelioma 2C51.2 Phase 2 [4]
Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
Diffuse large B-cell lymphoma 2A81 Phase 1/2 [4]
Synovial sarcoma 2B5A Phase 1 [4]
Cross-matching ID
PubChem CID
66558664
CAS Number
CAS 1403254-99-8
TTD Drug ID
DMWP1BH
ACDINA Drug ID
D01463

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Enhancer of zeste homolog 2 (EZH2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DS-3201b DMI69E5 T-cell leukaemia 2A90 Phase 2 [5]
CPI-1205 DM3XWJ8 Prostate cancer 2C82.0 Phase 1/2 [4]
SHR2554 DMMUCH0 Prostate cancer 2C82.0 Phase 1/2 [6]
CPI-0209 DMJEXLI Solid tumour/cancer 2A00-2F9Z Phase 1/2 [7]
DS-3201 DMRLPFG Acute lymphoblastic leukaemia 2A85 Phase 1 [4]
HH2853 DMQIE58 Non-hodgkin lymphoma 2B33.5 Phase 1 [8]
GSK2816126 DMJDVW4 Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
PF-06821497 DML3WT6 Diffuse large B-cell lymphoma 2A81 Phase 1 [10]
PMID28394193-Compound-56 DMQRFZK N. A. N. A. Patented [11]
PMID28394193-Compound-46 DMYMPNA N. A. N. A. Patented [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Enhancer of zeste homolog 2 (EZH2) TT9MZCQ EZH2_HUMAN Inhibitor [1]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209.
6 Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
7 ClinicalTrials.gov (NCT04104776) A Study of CPI-0209 in Patients With Advanced Tumors. U.S. National Institutes of Health.
8 Clinical pipeline report, company report or official report of HaiHe Biopharma.
9 National Cancer Institute Drug Dictionary (drug id 756211).
10 Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497). J Med Chem. 2018 Feb 8;61(3):650-665.
11 EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.